Priors rates this Established — 88 out of 100, updated weekly. Yes — this looks well established. On the claim that 177Lu-PSMA-617 (lutetium vipivotide tetraxetan) significantly improves overall survival and radiographic progression-free survival in PSMA-positive mCRPC after prior AR inhibitor and docetaxel (VISION trial), its four-agent AI review panel weighs 20 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Targeted Therapy Prostate Cancer review.